Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (865)	12/3/2003 8:16:14 PM
From: tuck	Read Replies (1) \| Respond to of 1005

>.AUSTIN, Texas, Dec. 3 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - News) today announced the completion of its offering of approximately 2.86 million shares of its common stock at a price of $7.00 per share. Introgen received gross proceeds of approximately $20 million. SG Cowen Securities Corporation acted as managing placement agent for the offering. The shares were offered on Wednesday, November 26, 2003 and were registered pursuant to a shelf registration statement relating to a total of up to $100 million of Introgen's securities which was declared effective by the U.S. Securities and Exchange Commission on August 25, 2003.<< snip Cheers, Tuck